Biomarin Pharmaceutical (BMRN) Institutional Ownership
13F filers reported holding 19.7% of Biomarin Pharmaceutical (BMRN) shares as of Sep 30, 2026, across 308 filers.
- Held by 13F filers
- 19.7%
- Sep 30, 2026
- 13F filers
- 308
- quarter ended Sep 30, 2026
- 13F value
- $2.3B
- 38.1M shares
- Quarter's fund flow
- Mild accumulation
- 46 new · 27 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Friberg Gregory R | EVP, Chief R&D Officer | Disposed · Tax withholding | 4,086 | $60.00 | ↗ |
| Sep 10, 2026 | Plenge Robert M | director | Acquired · Grant / award | 6,140 | — | ↗ |
| Sep 2, 2026 | Davis George Eric | EVP, Chief Legal Officer | Disposed · Open-market sale | 17,557 | $66.28 | ↗ |
| Jun 2, 2026 | Countouriotis Athena | director | Acquired · Grant / award | 7,490 | — | ↗ |
| Jun 2, 2026 | Walbert Timothy P | director | Acquired · Grant / award | 7,490 | — | ↗ |
| Jun 2, 2026 | Ho Maykin | director | Acquired · Grant / award | 7,490 | — | ↗ |
| Jun 2, 2026 | HOMBACH ROBERT J. | director | Acquired · Grant / award | 7,490 | — | ↗ |
| Jun 2, 2026 | Enyedy Mark J | director | Acquired · Grant / award | 7,490 | — | ↗ |
| Jun 2, 2026 | Dere Willard H | director | Acquired · Grant / award | 7,490 | — | ↗ |
| Jun 2, 2026 | CLARK IAN T | director | Acquired · Grant / award | 7,490 | — | ↗ |
| Jun 2, 2026 | Bodem Barbara W. | director | Acquired · Grant / award | 7,490 | — | ↗ |
| Jun 2, 2026 | ANDERSON ELIZABETH M | director | Acquired · Grant / award | 7,490 | — | ↗ |
| May 20, 2026 | Hubbard Cristin | EVP, Chief Commercial Officer | Disposed · Tax withholding | 2,318 | $50.20 | ↗ |
| May 7, 2026 | Friberg Gregory R | EVP, Chief R&D Officer | Disposed · Open-market sale | 3,281 | $53.85 | ↗ |
| Mar 18, 2026 | Davis George Eric | EVP, Chief Legal Officer | Disposed · Tax withholding | 1,273 | $56.05 | ↗ |
| Mar 17, 2026 | Guyer Charles Greg | EVP, Chief Technical Officer | Disposed · Tax withholding | 1,693 | $56.05 | ↗ |
| Mar 17, 2026 | Mueller Brian | EVP, Chief Financial Officer | Disposed · Tax withholding | 2,117 | $56.05 | ↗ |
| Mar 17, 2026 | Hardy Alexander | Chief Executive Officer | Disposed · Tax withholding | 4,252 | $56.05 | ↗ |
| Mar 17, 2026 | Hubbard Cristin | EVP, Chief Commercial Officer | Disposed · Tax withholding | 1,245 | $56.05 | ↗ |
| Mar 17, 2026 | Friberg Gregory R | EVP, Chief R&D Officer | Disposed · Tax withholding | 1,629 | $56.05 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Biomarin Pharmaceutical do institutions hold?
13F filers reported holding 19.7% of Biomarin Pharmaceutical's shares as of Sep 30, 2026, across 308 filers.
How many 13F filers hold Biomarin Pharmaceutical?
Biomarin Pharmaceutical was held by 308 13F filers as of Sep 30, 2026.
Not investment advice.

